Original Article

Impact of Tracheal Mucosa Involvement on Clinical Characteristics of Sarcoidosis

Authors: Ding Xin-Min, MD, Xu Qin-Zhi, MD, Duan Yun-You, MMed, Zhang Chun-Yan, MMed, Pen Chao-Sheng, MMed, Ning Hao-Yong, MD, Li Yong-Qun, MMed, Meng Ji-Guang, MMed, Nie Zhou-Shan, MMed, Feng Hua-Song, MMed

Abstract

Objectives: To investigate the impact of tracheal mucosa involvement on the clinical features of sarcoidosis.


Methods: The clinical data of sarcoidosis patients with (Group A, n = 26) and without (Group B, n = 61) tracheal mucosa involvement were evaluated retrospectively.


Results: The proportion of patients suffering from cough in Group A was 92.3%, which was significantly higher than that in Group B (49.2%). The level of serum angiotensin-converting enzyme I (SACE) in Group A (60.7 ± 27.8 IU/L) was significantly higher than that in Group B (44.5 ± 31.9 IU/L). The proportion of lymphocytes in the bronchoalveolar lavage fluid (BALF) in Group A was significantly higher than that of Group B (45.3 ± 16.8% and 36.7 ± 15.1%, respectively; P = 0.047). The ratio of CD4 to CD8 in Group A was significantly higher than that in Group B (7.6 ± 5.4 and 3.1 ± 3.2, respectively; P = 0.005). In Group A, 84.6% patients received drug treatment, with a spontaneous remission rate of 15.4%. In Group B, 50.2% patients received drug treatment and the spontaneous remission rate was as high as 49.2%.


Conclusions: Sarcoidosis with tracheal mucosa involvement that can lead to cough and other respiratory symptoms, may be a manifestation of sarcoidosis activity, and usually requires drug treatment (including corticosteroid treatment).

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), The European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736-755.
 
2. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153-2165.
 
3. Mihailovic-Vucinic V, Jovanovic D. Pulmonary sarcoidosis. Clin Chest Med. 2008;29:459-473.
 
4. Polychronopoulos VS, Prakash UB. Airway involvement in sarcoidosis. Chest. 2009;136:1371-1380.
 
5. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest. 2001;120:881-886.
 
6. Biller H, Zissel G, Ruprecht B, et al. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J. 2006;8:1085-1090.
 
7. Baughman RP. Sarcoidosis. New York, Taylor & Francis Group, 2006:435-440.
 
8. Drent M, Mansour K, Linssen C. Bronchoalveolar lavage in sarcoidosis. Semin Respir Crit Care Med. 2007;28:486-495.
 
9. Danila E, Jurgauskiene L, Norkuniene J, et al. BAL fluid cells in newly diagnosed pulmonary sarcoidosis with different clinical activity. Ups J Med Sci. 2009;114:26-31.
 
10. Fishman AP, Elias JA, Fishman JA, et al. Fishman's Pulmonary Diseases and Disorders. 4th ed. New York, McGraw-Hill Companies; 2008:1125-1142.
 
11. Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med. 2008;102:1-9.